Galectin Therapeutics (GALT) Retained Earnings (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Retained Earnings of -$437.6 million for Q1 2026, down 247.53% year-over-year from $296.6 million in Q1 2025, and down 1.17% quarter-over-quarter from -$432.5 million in Q4 2025.
Galectin Therapeutics (GALT) Retained Earnings (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$437.6 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 247.53% year-over-year to -$437.6 million; the TTM figure through Mar 2026 stood at -$437.6 million (down 247.53% YoY), while the FY2025 annual figure was -$432.5 million, down 246.02% from the prior year.
- Retained Earnings for Q1 2026 stood at -$437.6 million, down from -$432.5 million in the prior quarter.
- The five-year high for Retained Earnings was $301.1 million in Q3 2025, with the low at -$437.6 million in Q1 2026.
- The 5-year median for Retained Earnings is -$298.9 million (2022), against an average of -$57.6 million.
- The sharpest annual moves came in 2024 and 2026: Retained Earnings soared 185.61% in 2024, then slumped 247.53% in 2026.
- Galectin Therapeutics' Retained Earnings stood at -$309.6 million in 2022, then dropped by 14.47% to -$354.4 million in 2023, then surged by 183.59% to $296.2 million in 2024, then slumped by 246.02% to -$432.5 million in 2025, then decreased by 1.17% to -$437.6 million in 2026.
- Business Quant data shows GALT's Retained Earnings at -$437.6 million in Q1 2026, -$432.5 million in Q4 2025, and $301.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | -437.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -437.61 Mn |
| Dec 31, 2025 | -432.55 Mn |
| Sep 30, 2025 | 301.13 Mn |
| Jun 30, 2025 | -418.76 Mn |
| Mar 31, 2025 | 296.63 Mn |
| Dec 31, 2024 | 296.22 Mn |
| Sep 30, 2024 | 294.78 Mn |
| Jun 30, 2024 | 293.87 Mn |
| Mar 31, 2024 | -365.87 Mn |
| Dec 31, 2023 | -354.37 Mn |
| Sep 30, 2023 | -344.31 Mn |
| Jun 30, 2023 | 276.85 Mn |
| Mar 31, 2023 | -321.09 Mn |
| Dec 31, 2022 | -309.57 Mn |
| Sep 30, 2022 | -298.87 Mn |
| Jun 30, 2022 | 272.77 Mn |
| Mar 31, 2022 | 272.11 Mn |
| Dec 31, 2021 | 271.00 Mn |
| Sep 30, 2021 | 270.35 Mn |
| Jun 30, 2021 | 269.66 Mn |